Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

By sjmartinez • October 30, 2023

Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, Sakamoto N, Kato N, Nakano M, Jia J, Vogel A. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. PMID: 37901766; PMCID: PMC10601852.

Tags: Albumin-bilirubin grade, Atezolizumab, Bevacizumab, Hematology/Oncology, Publications, Unresectable hepatocellular carcinoma

PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation

Zaikos TD, Pham V, Chou TC, Moran JA, Turner SR, Yu BH, Hourani R, Ranjan A, Zack JA, Wender PA, Marsden MD. PKC inhibitors reveal[...]

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]